BioCentury
ARTICLE | Company News

Enzon drug delivery, infectious, cancer news

February 9, 2009 8:00 AM UTC

Knott Partners, which owns about 4% of Enzon, sent a letter to CEO Jeffery Buchalter and the board suggesting immediate action, including a share buyback plan; an auction for the entire company or its...